Date: Thursday 05 Sep 2013
LONDON (ShareCast) - ValiRx, a biopharmaceutial company with a focus on the treatment of cancer, said while losses had widened in the first half it had made “excellent” advances in its clinical and pre-clinical development pipeline.
It reiterated that it expected results from the first stage of clinical trials for its VAL201 anti-cancer therapeutic product by the end of the year.
It said its VAL 101 drug candidate, which will benefit from a further Eurostars grant for up to €1.6m, has continued to show good progress in the pre-clinical phase of trials.
Earlier this year the life sciences group appointed medical monitoring officer Alan Boyd to oversee VAL201's clinical development.
Nick Thorniley, Non-Executive Chairman, said: “These steps forward permit your company an increasingly confident perspective and I also look forward to reporting on the results of our clinical trial, which are anticipated in late December 2013.”
Half year losses widened to £1.6m from £1.1m after it spent more on research and development. No dividend will be paid. Its cash pile stood at £1.2m at the end of June.
Shares in ValiRX were up 6.7% at 0.4p at 12:00 on Thursday.
TB
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 3.25p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 14.13p |
52 Week Low | 3.20p |
Volume | 63,583 |
Shares Issued | 132.35m |
Market Cap | £4.30m |
RiskGrade | 435 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:21 | 8,692 @ 3.20p |
16:07 | 11,683 @ 3.20p |
14:31 | 1,000 @ 3.20p |
13:02 | 6 @ 3.20p |
12:41 | 5,256 @ 3.20p |
You are here: research